single50MG
SS-31
50MG Protocol
SS-31 50MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks; limited data exists beyond 12 weeks
Reconstitution
3.0 mL BAC water
Supports mitochondrial membrane stability and ETC efficiency
May increase ATP output and reduce pathological ROS
Functional gains reported in Barth syndrome trial context
Broad protective effects described in preclinical models
1
Reconstitution Requirements
- 3.0 mL BAC water
Escalation steps: 2
Defined through week 8
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 5 mg (5000 mcg) | 30 |
| 2 | Weeks 3–8 | 10 mg (10,000 mcg) | 60 |
Inject once daily
8–12 weeks; limited data exists beyond 12 weeks
The SS-31 protocol explains a mechanism centered on mitochondrial membrane biology rather than conventional receptor agonism. SS-31 (elamipretide) is described as entering cells and selectively accumulating in the inner mitochondrial membrane, where it binds cardiolipin. Because cardiolipin helps organize electron-transport-chain (ETC) complexes and supports cristae integrity, stabilizing cardiolipin–protein interactions is presented as improving ETC efficiency. Downstream, the page describes reduced pathological reactive oxygen species formation and enhanced ATP production in energy-demanding tissues. The protocol also contextualizes SS-31 across research and clinical development, citing broad preclinical protection across multiple disease models and noting that human trials generally reported favorable tolerability without dose-limiting toxicity. The most consistent adverse observation highlighted is injection-site irritation; the page also flags that longer-term safety beyond relatively short study windows is less well characterized.
Injection-site reactions (redness/itching/transient discomfort)
Mild injection-site reactions were commonly reported
Limited long-term safety data beyond ~12 weeks
No serious adverse events directly attributed in published trials (per page)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)